Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

Inclusion Criteria:

- Written informed consent must be obtained before any assessment is performed.

- Male and female heart failure patients with body weight <160 kg, on standard therapy
including a stable dose of furosemide 40-240 mg/day orally (p.o). or equivalent dose
of loop diuretics, reduced systolic function (LVEF ≤ 45% measured within the past 6
months), BNP ≥ 100 pg/mL or NT-pro-BNP of ≥ 400 pg/mLNYHA Class II or III, and
worsening symptoms, e.g. fatigue, dyspnea, breathlessness within 3 months

- Mild to moderate renal impairment

Exclusion criteria:

- Systolic blood pressure (SBP) < 110 mm Hg at the time of randomization

- Administration of intravenous radiographic contrast agent within 72 hours prior to
randomization or acute contrast-induced nephropathy at the time of randomization

- Current use of non-steroidal antiinflammatory drugs (NSAIDs)

- Current or planned (through the completion of study drug infusion) treatment with any
i.v. therapies, including vasodilators (including nesiritide), positive inotropic
agents, vasopressors, levosimendan, or mechanical support (intra-aortic balloon pump,
endotracheal intubation, mechanical ventilation, or any ventricular assist device).

- Clinically significant hepatic impairment defined as hepatic encephalopathy of any
degree or total bilirubin > 50 μmol/l (3 mg/dl) or, if patient is not on warfarin
therapy, INR > 2.0 (or Prothrombin Time > 2 * ULN)

Other protocol-defined inclusion/exclusion criteria may apply.